research use only

Deutenzalutamide Androgen Receptor antagonist

Name: Deutenzalutamide
Brand: Selleck Chemicals
SKU: E1502
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E1502

Deutenzalutamide (HC-1119, MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. It can be used in a treatment of advanced prostate cancer.

Chemical Structure

Molecular Weight: 467.46

Jump to

Quality Control

Batch: E150201 DMSO]93 mg/mL]false]Ethanol]8 mg/mL]false]Water]Insoluble]false Purity: 99.33%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS
Datasheet

99.33

Related Targets	Adrenergic Receptor Estrogen/progestogen Receptor GPR Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES THR
Other Androgen Receptor Products	Bavdegalutamide (ARV-110) RU58841 Galeterone EPI-001 Cyproterone Acetate 3,3'-Diindolylmethane GSK-2881078 Chlormadinone acetate GDC-2992 JNJ-63576253 (TRC-253)

Solubility

In vitro
Batch:

DMSO : 93 mg/mL (198.94 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 8 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.650mg/ml (9.95mM)	Taking the 1 mL working solution as an example, add 50 μL of 93 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.650mg/ml (9.95mM)	Taking the 1 mL working solution as an example, add 50 μL of 93 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	467.46	Formula	C₂₁H₁₃D₃F₄N₄O₂S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1443331-82-5	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Mechanism of Action

Targets/IC₅₀/Ki	Androgen Receptor 36 nM
References	[1] https://pubmed.ncbi.nlm.nih.gov/19359544/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04986176	Unknown status	COVID-19 Respiratory Infection	Applied Biology Inc.\|Hinova Pharmaceuticals Inc.	April 15 2022	Phase 3
NCT01901133	Completed	Pharmacokinetics of MDV3100\|Healthy Subjects\|Kidney Diseases	Astellas Pharma Europe B.V.\|Medivation Inc.\|Astellas Pharma Inc	October 2011	Phase 1
NCT01913379	Completed	Healthy Subjects\|Pharmacokinetics\|Drug-Drug Interaction	Astellas Pharma Europe B.V.\|Medivation Inc.\|Astellas Pharma Inc	August 2011	Phase 1
NCT01911715	Completed	Healthy Subjects\|Pharmacokinetics of MDV3100	Astellas Pharma Europe B.V.\|Medivation Inc.\|Astellas Pharma Inc	April 2011	Phase 1
NCT00510718	Completed	Prostate Cancer\|Hormone Refractory Prostate Cancer	Pfizer\|Astellas Pharma Inc\|Medivation LLC a wholly owned subsidiary of Pfizer Inc.	July 23 2007	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):